Evidence map›Paper›PMID 36510275›Full record

ReviewParasites & vectors2022

Drugs for neglected tropical diseases: availability of age-appropriate oral formulations for young children.

Issraa Al-Obaidi, Anna K Krome, Karl G Wagner, Kenneth Pfarr, Annette C Kuesel, Hannah K Batchelor

Open access · goldAbstract readReview
In one paragraph

Review in Parasites & vectors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Issraa Al-ObaidiStrathclyde Institute of Pharmacy and Biomedical Sciences, 161 Cathedral Street, Glasgow, G4 0RE, UK.
Anna K KromeDepartment of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, 53121, Bonn, Germany.
Karl G WagnerDepartment of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, 53121, Bonn, Germany.
Kenneth PfarrInstitute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Bonn, Germany.
Annette C KueselUNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland.
Hannah K BatchelorStrathclyde Institute of Pharmacy and Biomedical Sciences, 161 Cathedral Street, Glasgow, G4 0RE, UK. Hannah.batchelor@strath.ac.uk.
University of Bonn · DEUniversity of Strathclyde · GBGerman Center for Infection Research · DEWorld Health Organization · CH

Funding

European and Developing Countries Clinical Trials Partnership INTER/EDCTP/19/14338294/MiniMox/VaillantWorld Health Organization 001
6 · The paper itself

Abstract

It is recognised that paediatric indications and age-appropriate formulations are required to ensure that paediatric populations receive appropriate pharmacotherapeutic treatment. The lack of information on dosing, efficacy and safety data (labelling) is a well-recognised problem for all diseases affecting children. For neglected tropical diseases, the fact that they affect to a large extent poor and marginalised populations in low- and middle-income countries means that there is a low economic return on investment into paediatric development activities compared to other diseases [e.g. human immunodeficiency virus (HIV)]. This review provides an introduction to issues affecting the availability and development of paediatric population-relevant data and appropriate formulations of drugs for NTDs. We are summarising why age-appropriate formulations are important to ensure treatment efficacy, safety and effectiveness, outline initiatives to increase the number of paediatric indications/labelling and age-appropriate formulations, provide an overview of publicly available information on the formulations of oral drugs for NTDs relative to age appropriateness and give an introduction to options for age-appropriate formulations. The review completes with 'case studies' of recently developed paediatric formulations for NTDs, complemented by case studies for fixed-dose combinations for HIV infection in children since such formulations have not been developed for NTDs.

Indexed as

HIV InfectionsTropical MedicineChildChild, PreschoolDrug CompoundingHumansNeglected DiseasesNeglected tropical diseasesNTDOral formulationPaediatric age-appropriate formulationsPaediatric indicationsPreventive chemotherapyWHO Roadmap

Identifiers

PMID36510275
PMCPMC9746163
OpenAlexW4311409316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.